Shrink Nanotechnologies has filed certain patent application for its advanced tissue engineering technology platform CellAlign.
Shrink Nanotechnologies said that CellAlign allows for the structured alignment of biological tissues, particularly tissues which naturally grow in a linear fashion (like cardiac or nerve tissue).
CellAlign’s key feature is a micro-fabricated substrate with non-periodic (or random) linear patterned grooves that allow for the alignment of cells along a single axis. The alignment condition is paramount for many cellular processes and is most physiologically relevant to biological tissue.
Mark Baum, president of Shrink Nanotechnologies, said: “CellAlign has the potential to grow sheets of living tissues that may one day act as ‘band-aids’ to patch and repair, and possibly regenerate, damaged or diseased organs.
“Clinical practices and medical specialties are increasingly turning to cellular-based therapies to solve some of the world’s most perplexing health maladies. As our intellectual property position improved with CellAlign, future licensing potential represents a significant market opportunity for Shrink.”
Shrink Nanotechnologies owns and develops proprietary and patent-pending nano-sized technologies, components and product systems.